Viral Infections and Antiviral Therapies
-10%
portes grátis
Viral Infections and Antiviral Therapies
Dhara, Amal Kumar; Nayak, Amit Kumar
Elsevier Science & Technology
11/2022
808
Mole
Inglês
9780323918145
15 a 20 dias
1610
Descrição não disponível.
Section I: Introduction 1. Introduction to antiviral therapy
Section II: Viral infections and transmission 2. Emerging viral diseases 3. Evolution and transmission of viruses 4. Mode of viral infections and transmissions 5. Transmission and Intervention Dynamics of SARS-CoV-2 6. Sexually transmitted viral infections 7. Testing of viral infections 8. Electron microscopic methods for virus diagnosis
Section III: Antiviral agents and therapeutics 9. Virotherapy 10. Challenges in designing antiviral agents 11. Anti-influenza agents 12. Anti-herpes virus agents 13. Antiretroviral Therapies 14. Rotavirus and anti-rotaviral agents: Trends and advances 15. Current therapeutic strategies and novel antiviral compounds for the treatment of non-polio enteroviruses 16. Antiviral agents against flaviviruses 17. Pathophysiology of HIV and strategies to eliminate AIDS as a public health threat 18. Herbal drugs to combat viruses 19. Strategies for delivery of antiviral agents 20. Nanovesicles for delivery of antiviral agents 21. Antiviral biomaterials 22. Antiviral biomolecules from marine inhabitantsBalasubramanian 23. Plant polysaccharides as antiviral agents 24. Antiviral peptides against dengue virus 25. mRNA vaccines for COVID-19 26. Immunotherapy as an emerging and promising tool against viral infections 27. Role of nutraceuticals as immunomodulators to combat viruses
Section IV: Others 28. In vitro and in vivo approaches for evaluating antiviral efficacy 29. Clinical trials and regulatory considerations of antiviral agents 30. Future perspectives of antiviral therapy
Section II: Viral infections and transmission 2. Emerging viral diseases 3. Evolution and transmission of viruses 4. Mode of viral infections and transmissions 5. Transmission and Intervention Dynamics of SARS-CoV-2 6. Sexually transmitted viral infections 7. Testing of viral infections 8. Electron microscopic methods for virus diagnosis
Section III: Antiviral agents and therapeutics 9. Virotherapy 10. Challenges in designing antiviral agents 11. Anti-influenza agents 12. Anti-herpes virus agents 13. Antiretroviral Therapies 14. Rotavirus and anti-rotaviral agents: Trends and advances 15. Current therapeutic strategies and novel antiviral compounds for the treatment of non-polio enteroviruses 16. Antiviral agents against flaviviruses 17. Pathophysiology of HIV and strategies to eliminate AIDS as a public health threat 18. Herbal drugs to combat viruses 19. Strategies for delivery of antiviral agents 20. Nanovesicles for delivery of antiviral agents 21. Antiviral biomaterials 22. Antiviral biomolecules from marine inhabitantsBalasubramanian 23. Plant polysaccharides as antiviral agents 24. Antiviral peptides against dengue virus 25. mRNA vaccines for COVID-19 26. Immunotherapy as an emerging and promising tool against viral infections 27. Role of nutraceuticals as immunomodulators to combat viruses
Section IV: Others 28. In vitro and in vivo approaches for evaluating antiviral efficacy 29. Clinical trials and regulatory considerations of antiviral agents 30. Future perspectives of antiviral therapy
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
?AIDS; Acquired immunodeficiency syndrome; Alginate; Animal viruses; Anti-influenza agents; Antibody therapy; Antibody-based therapies; Antiherpetic agents; Antiretroviral therapy; Antiretroviral treatment; Antirotaviral therapeutics; Antiviral; Antiviral activity; Antiviral agents; Antiviral biomaterials; Antiviral peptides; Antiviral therapy; Antivirals; Aspergillipeptides; COVID-19; CTE; Cancer; Carbon-based drug delivery systems; Carrageenan; Checkpoint inhibition; Chemical modifications; Chikungunya; Chimeric antigen receptor T cells; Chitin; Chitosan; Clinical trials; Combination therapy; Combinatorial therapy; Coronavirus; DAAD; Defensin therapy; Dengue; Dengue virus; Drug delivery; Drug design; EC50; Ebola; Electron microscopy; Elimination of AIDS; Encephalitis; Enteroviruses; Ethnomedicines; FDA; Flavivirus; Fluid therapy; Fucoidan; HCV; HIV; HTLV; Hepatitis A; Herd immunity; Herpes simplex virus; Herpes virus; Human immunodeficiency virus; Human papillomavirus; Hydrogel; IC50; Immunity; Immunogenic cell death; Immunomodulatory; Immunotherapy; In vitro testing; In vivo testing; Incubation; Infection; Infectious disease; Influenza virus; Intervention; LNPs; Lipid-based drug delivery systems; MRNA; Marine polysaccharides; Marine-derived peptides; Medicinal chemistry; Medicinal plants; Metal-based nanoparticles; Mode; Modern therapy; Monotherapy; Mutant strains; Mutation; NP-nanoparticles; NS2B-NS3; Nanodecoys or nanosponges; Nanomaterials; Nanomedicine; Nanovaccines; Nanovesicles; Neoechinulin B; Novel virus; Nucleoside or nucleotide analogs; Nutraceuticals; Omics era; Oncolytic virus; PCR
Section I: Introduction 1. Introduction to antiviral therapy
Section II: Viral infections and transmission 2. Emerging viral diseases 3. Evolution and transmission of viruses 4. Mode of viral infections and transmissions 5. Transmission and Intervention Dynamics of SARS-CoV-2 6. Sexually transmitted viral infections 7. Testing of viral infections 8. Electron microscopic methods for virus diagnosis
Section III: Antiviral agents and therapeutics 9. Virotherapy 10. Challenges in designing antiviral agents 11. Anti-influenza agents 12. Anti-herpes virus agents 13. Antiretroviral Therapies 14. Rotavirus and anti-rotaviral agents: Trends and advances 15. Current therapeutic strategies and novel antiviral compounds for the treatment of non-polio enteroviruses 16. Antiviral agents against flaviviruses 17. Pathophysiology of HIV and strategies to eliminate AIDS as a public health threat 18. Herbal drugs to combat viruses 19. Strategies for delivery of antiviral agents 20. Nanovesicles for delivery of antiviral agents 21. Antiviral biomaterials 22. Antiviral biomolecules from marine inhabitantsBalasubramanian 23. Plant polysaccharides as antiviral agents 24. Antiviral peptides against dengue virus 25. mRNA vaccines for COVID-19 26. Immunotherapy as an emerging and promising tool against viral infections 27. Role of nutraceuticals as immunomodulators to combat viruses
Section IV: Others 28. In vitro and in vivo approaches for evaluating antiviral efficacy 29. Clinical trials and regulatory considerations of antiviral agents 30. Future perspectives of antiviral therapy
Section II: Viral infections and transmission 2. Emerging viral diseases 3. Evolution and transmission of viruses 4. Mode of viral infections and transmissions 5. Transmission and Intervention Dynamics of SARS-CoV-2 6. Sexually transmitted viral infections 7. Testing of viral infections 8. Electron microscopic methods for virus diagnosis
Section III: Antiviral agents and therapeutics 9. Virotherapy 10. Challenges in designing antiviral agents 11. Anti-influenza agents 12. Anti-herpes virus agents 13. Antiretroviral Therapies 14. Rotavirus and anti-rotaviral agents: Trends and advances 15. Current therapeutic strategies and novel antiviral compounds for the treatment of non-polio enteroviruses 16. Antiviral agents against flaviviruses 17. Pathophysiology of HIV and strategies to eliminate AIDS as a public health threat 18. Herbal drugs to combat viruses 19. Strategies for delivery of antiviral agents 20. Nanovesicles for delivery of antiviral agents 21. Antiviral biomaterials 22. Antiviral biomolecules from marine inhabitantsBalasubramanian 23. Plant polysaccharides as antiviral agents 24. Antiviral peptides against dengue virus 25. mRNA vaccines for COVID-19 26. Immunotherapy as an emerging and promising tool against viral infections 27. Role of nutraceuticals as immunomodulators to combat viruses
Section IV: Others 28. In vitro and in vivo approaches for evaluating antiviral efficacy 29. Clinical trials and regulatory considerations of antiviral agents 30. Future perspectives of antiviral therapy
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
?AIDS; Acquired immunodeficiency syndrome; Alginate; Animal viruses; Anti-influenza agents; Antibody therapy; Antibody-based therapies; Antiherpetic agents; Antiretroviral therapy; Antiretroviral treatment; Antirotaviral therapeutics; Antiviral; Antiviral activity; Antiviral agents; Antiviral biomaterials; Antiviral peptides; Antiviral therapy; Antivirals; Aspergillipeptides; COVID-19; CTE; Cancer; Carbon-based drug delivery systems; Carrageenan; Checkpoint inhibition; Chemical modifications; Chikungunya; Chimeric antigen receptor T cells; Chitin; Chitosan; Clinical trials; Combination therapy; Combinatorial therapy; Coronavirus; DAAD; Defensin therapy; Dengue; Dengue virus; Drug delivery; Drug design; EC50; Ebola; Electron microscopy; Elimination of AIDS; Encephalitis; Enteroviruses; Ethnomedicines; FDA; Flavivirus; Fluid therapy; Fucoidan; HCV; HIV; HTLV; Hepatitis A; Herd immunity; Herpes simplex virus; Herpes virus; Human immunodeficiency virus; Human papillomavirus; Hydrogel; IC50; Immunity; Immunogenic cell death; Immunomodulatory; Immunotherapy; In vitro testing; In vivo testing; Incubation; Infection; Infectious disease; Influenza virus; Intervention; LNPs; Lipid-based drug delivery systems; MRNA; Marine polysaccharides; Marine-derived peptides; Medicinal chemistry; Medicinal plants; Metal-based nanoparticles; Mode; Modern therapy; Monotherapy; Mutant strains; Mutation; NP-nanoparticles; NS2B-NS3; Nanodecoys or nanosponges; Nanomaterials; Nanomedicine; Nanovaccines; Nanovesicles; Neoechinulin B; Novel virus; Nucleoside or nucleotide analogs; Nutraceuticals; Omics era; Oncolytic virus; PCR
